Nisin or Chitosan Enhance the Antimicrobial Activity of Ceftiofur Against Antibiotic-Resistant Staphylococcus aureus and Have Antibiofilm Effects Authors: Mónica G. Sánchez-Ceja, Jaime L. Esquivel-Alejo, Ricardo I. Medina-Estrada, Rafael Jiménez-Mejía, Gustavo Santoyo, Joel E. López-Meza, Pedro D. Loeza-Lara Published: 2025 ABSTRACT Mastitis is one of the major diseases affecting dairy cattle worldwide. Antibiotic therapy remains the most widely used treatment. However, its effectiveness has been compromised due to the selection of antibiotic-resistant and biofilm-producing pathogenic bacteria. This promotes the search for alternatives that increase the antibacterial and antibiofilm efficacy of antibiotics such ceftiofur (CFT). Nisin (N) and chitosan (CH) may possess these properties. The aim of this study was to evaluate whether N + CFT and CH + CFT combinations enhance the antibacterial activity of the antibiotic on Staphylococcus aureus associated with bovine mastitis, as well as its antibiofilm effect. Two clinical isolates of S. aureus (AMC-43 and AMC-48) and the reference strain ATCC 27543 resistant to CFT were used. Through the microdilution method in 96-well microplates, the combination of sub-inhibitory concentrations of N (320 µg/mL) and CH (400 µg/mL) with CFT (1, 2, 4, and 8 µg/mL) significantly reduced bacterial growth; however, the CH + CFT mixtures were the most efficient. The crystal violet staining method and live cell plating showed antibiofilm activity in biofilm synthesis and in the reduction in living bacterial cells located inside this preformed structure. These results highlight N and CH as potential agents for the prevention or control of bovine mastitis. 1. Introduction Mastitis or the inflammation of the mammary gland is the most costly and prevalent disease in dairy herds. Globally, millions of dollars are lost annually to the disease which markedly impacts dairy farming. The multifactorial etiology of the disease complicates its treatment. However, Gram-positive and Gram-negative microorganisms are prominent as causal agents [1]. Among these, the most important species capable of causing inflammation belong to a few groups, which are categorized as contagious and environmental pathogens according to their reservoir and transmission mechanisms [2]. Staphylococcus aureus is the most frequently isolated contagious pathogen from milk samples of cows with clinical and subclinical mastitis [3]. This pathogen causes the most virulent forms of the disease and poses one of the greatest challenges to milk production worldwide [4]. Antibiotic therapy is the primary strategy used to control bacterial infections, especially β-lactam antibiotics such as ceftiofur and oxacillin [5]. However, this therapy fails due to prolonged and inappropriate use of antibiotics. This increases bacterial selection pressure, which has led to the development of resistant strains. Added to this is the rapid spread of resistance determinants among pathogenic microorganisms [6]. Resistance of S. aureus strains to penicillin and its variants implicated in mastitis (β-lactams) is perhaps the most recognized form of resistance, ranging between 30 and 90% with variations from one region to another where dairy herds exist [7]. S. aureus strains such as methicillin-resistant S. aureus (MRSA) that are resistant to multiple antibiotics are common [6]. During bovine mastitis development, some S. aureus strains utilize virulence factors, such as biofilm matrix, to establish themselves in the host [8]. Furthermore, biofilms might provide protection against antimicrobial strategies owing to the low diffusion capacity of antibiotics through biofilm components [9]. Both bacterial strategies, resistance to antibiotics and biofilm synthesis, allow the development of recurrent intramammary infections. Lack of novel antibiotics from the pharmaceutical industry constitutes a major challenge for the veterinary sector and global public health [5]. All of this underlines the need to integrate innovative strategies to improve the efficacy of traditional antibiotics, inhibit biofilm synthesis, and help control recurrent intramammary infections. Biocompounds that, combined with antibiotics at sub-inhibitory concentrations, improve the antibiotic’s efficacy against resistant bacteria, possess antibiofilm properties, and are safe for human and animal health are receiving increasing attention [10,11]. Nisin is a cationic peptide of 34 amino acids produced by Lactococcus lactis subsp. lactis, with antibacterial activity, particularly against Gram-positive bacteria. Recognized as a safe additive, this peptide has been proposed as a potential therapeutic agent for control of bacterial infections of the mammary gland [12]. Chitosan is a cationic polymer of natural origin with biological activity against Gram-positive and Gram-negative pathogens [13]. This biodegradable and nontoxic biocompound has been proposed for various biomedical therapies [14]. Both biocompounds have exhibited antibacterial activity against bovine-mastitis-associated S. aureus isolates [7]. However, their ability to enhance the antibacterial effect of conventional antibiotics, like ceftiofur, and their effects on biofilm synthesis and the bacterial viability inside the biofilm remain unknown. Therefore, the aim of this study was to assess the enhancer effect of the combination of nisin or chitosan with ceftiofur on its antibiotic activity on antibiotic-resistant S. aureus, as well as the effect of the combinations on biofilm synthesis and bacterial viability within this preformed structure. 2. Materials and Methods 2.1. Bacterial Isolates and Growth Conditions Two isolates of bovine-mastitis-associated S. aureus including AMC-43 and AMC-48 were used. These clinical isolates were obtained from milk samples from cows diagnosed with clinical and subclinical mastitis (California mastitis test) from 34 dairy herds in the Ciénega de Chapala region, Michoacán, Mexico. The isolates were characterized microscopically (morphology), biochemically (Gram staining, catalase, coagulase, tellurite reduction, and lipolytic activity tests in Petri dishes with Baird Parker agar and growth on salt and mannitol agar), and molecularly (amplification of a fragment of the nuc gene, which encodes the thermostable nuclease of S. aureus) [7]. The certified S. aureus subsp. aureus ATCC (27543) strain, which was isolated from a clinical case of bovine mastitis, was used as positive control. Bacteria were cultured in nutrient agar (BD Bioxon®, Ciudad de México, Mexico) at 37 °C for 24 h and maintained at 4 °C until further use. Due to the nature of the research and the way the milk samples were obtained, approval from an ethics committee was not required. 2.2. Nisin and Chitosan Antibacterial Activity and Ceftiofur Resistance Assays Following the manufacturer’s instructions, the antimicrobial peptide nisin (N) (Nisina Raff®, Zapopan, Jalisco, Mexico) was dissolved in distilled water and sterilized by filtrating through 0.22 µm pore diameter membranes (Swinnex®, Darmstadt, Germany, Merck Millipore®). On the other hand, polymer chitosan (CH) (≥90% deacetylation grade, Future Foods®, Ciudad de México, Mexico) was dissolved in 1% acetic acid (J.T. Baker®, Radnor, PA, USA), continuously stirred at 500 rpm for 6–8 h until the mixture was completely homogeneous. The solution pH was adjusted to 5.6 with NaOH (J.T. Baker®, USA) and sterilized at 120 °C for 15 min. The β-lactam antibiotic ceftiofur (CFT) (Vetranal®, Sigma Aldrich, St. Louis, MO, USA) was dissolved in sterile distilled water. The biocompounds and antibiotic were kept at 4 °C until further use. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of N, CH, and CFT were determined using the microdilution method in Mueller–Hinton broth (MHB) (BD Bioxon®, Mexico) in 96-well microplates (Celltreat®, Ayer, MA, USA), following the Clinical Laboratory Standards Institute (CLSI) [15] guidelines and the methodology of Ster et al. [16] with some modifications. Overnight bacterial cultures in MHB at 37 °C were adjusted to ~0.2 optical density (OD) at 600 nm (Thermo Fisher Scientific® spectrophotometer, Waltham, MA, USA), equivalent to approximately 4.8 × 106 CFU/mL (6.68 log). These cultures were incubated for 24 h at 37 °C in 96-well microplates in different concentrations of N, CH, and CFT with a final volume of 150 µL per well. Concentration ranges of 10–5120, 12.5–6400, and 1–2048 µg/mL were used for N, CH, and CFT, respectively. The highest concentrations were serially diluted (doubling dilutions) [5,16,17]. Resistance to CFT was confirmed by inoculating bacteria on Mueller–Hinton agar (MHA) plates containing the indicated antibiotic concentrations. MIC was defined as the minimum concentration of antibiotic or biocompounds that prevented bacterial growth: the concentration whose OD was equal to that inoculated (~0.2) after 24 h of incubation. Afterwards, the content of each well equal to or greater than the MIC was streaked on MHA plates and incubated at 37 °C to analyze bacterial growth 24 h after plating. The lowest concentration without visible bacterial colony growth was considered the MBC. S. aureus was considered resistant to CFT when it grew at a concentration ≥ of 8 µg/mL after 24 h of incubation [5,16,17]. MHB without S. aureus was used as a negative control of bacterial growth, while MHB containing S. aureus (~4.8 × 106 CFU/mL) and MHB containing S. aureus (~4.8 × 106 CFU/mL) and CFT (8 µg/mL) were used as a positive growth control. For CH, a second positive control of bacterial growth was used: MHB containing S. aureus (~4.8 × 106 CFU/mL), and the vehicle of CH (1% acetic acid, pH 5.6). The treatments evaluated were MHB with S. aureus (~4.8 × 106 CFU/mL) and the following N concentrations: 5120, 2560, 1280, 640, 320, 160, 80, 40, 20, and 10 µg/mL; as well as MHB with S. aureus (~4.8 × 106 CFU/mL) and the following CH concentrations: 6400, 3200, 1600, 800, 400, 200, 100, 50, 25, and 12.5 µg/mL; and MHB with S. aureus (~4.8 × 106 CFU/mL), as well as the next concentrations of the antibiotic CFT: 2048, 1024, 512, 256, 128, 64, 32, 16, 8, 4, 2, and 1 µg/mL. 2.3. Inhibition Assays of S. aureus by N, CH, CFT, and N + CFT and CH + CFT Combinations The antibacterial effect of N + CFT and CH + CFT combinations on antibiotic-resistant S. aureus was investigated using the microdilution method. Overnight bacterial cultures in MHB at 37 °C were adjusted to an OD of ~0.2 and incubated for 24 h at 37 °C in the presence of sub-inhibitory concentrations (sub-MICs) of N (320 µg/mL) and CH (400 µg/mL), combined with different concentrations of CFT (1, 2, 4, and 8 µg/mL), which represent the CFT breakpoint for S. aureus (8 μg/mL), while the rest are lower than this breakpoint (1, 2, and 4 μg/mL). For example, (320 + 1) means that the combination contained 320 µg/mL of N and 1 µg/mL of CFT, and so on. This also applied to the mixture of CH with CFT (400 + 1). The positive and negative controls for bacterial growth were MHB + S. aureus and MHB − S. aureus, respectively. The following treatments were evaluated: MHB + S. aureus + N; MHB + S. aureus + CH; MHB + S. aureus + N + CFT; MHB + S. aureus + CH + CFT. The reduction in bacterial growth was verified by measuring the OD of each treatment and quantifying the CFU/mL, which were expressed in logarithmic units, after 24 h of incubation in MHA plates. In addition, the logarithmic scale reduction factor (Log10) was calculated using Formula (1):(1)RF=Log10A−Log10(B) where A is the number of colonies recovered from the unexposed (control) and B is the number of colonies recovered from the exposed (test) to treatments. Using the average values of these counts, the microbial reduction percentages (MRP) were calculated according to Formula (2) [18]:(2)MRP=controlCFUmL−testCFUmLcontrolCFUmL×100 2.4. Biofilm Production Assays of S. aureus and Inhibition by N, CH, CFT, and N + CFT and CH + CFT Combinations To assess the inhibitory capacity of N, CH, CFT, and their corresponding combinations on the synthesis of S. aureus biofilms, the ability of the bacteria to produce this virulence factor was determined, followed by inhibition analysis. Biofilm synthesis was determined using the crystal violet staining methodology reported by Guzmán-Rodríguez et al. [19], with some modifications. Assays were performed in 96-well plates, where 150 µL of each bacterial culture grown in MHB adjusted to an OD of ~0.2 (600 nm) was placed. The plates were incubated for 24 h at 37 °C. Next, the wells were washed with phosphate-buffered saline (PBS), 150 µL of 0.5% crystal violet (Golden Bell®, Guadalajara, Mexico) was added, and plates were maintained for 15 min at room temperature (25 ± 2.0 °C). Subsequently, the dye was discarded, and the wells were washed twice with PBS. Finally, 150 µL of 33% acetic acid (Merk®, Naucalpan de Juárez, Estado de México, Mexico) was added, the plate was thoroughly mixed for homogenization, and the absorbance was read at 595 nm using a microplate spectrophotometer. The classification by Stepanović et al. [20] was used to categorize bacteria as non-biofilm producers (0), weak biofilm producers (+ or 1), moderate biofilm producers (++ or 2), and strong biofilm producers (+++ or 3) based on the OD values of the samples analyzed according to the following calculations:OD≤ODcontrol=non−biofilm producer;ODcontrol